[
    [
        {
            "time": "",
            "original_text": "[路演]贝达药业：埃克替尼不良反应发生率低于对照进口药",
            "features": {
                "keywords": [
                    "贝达药业",
                    "埃克替尼",
                    "不良反应",
                    "进口药"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "[路演]贝达药业：埃克替尼不良反应发生率低于对照进口药",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "[推荐评级]贝达药业(300558)年报点评：业绩符合预期 2018Q1凯美纳降价影响逐步消除 研发加速推进",
            "features": {
                "keywords": [
                    "贝达药业",
                    "年报",
                    "凯美纳",
                    "降价",
                    "研发"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[推荐评级]贝达药业(300558)年报点评：业绩符合预期 2018Q1凯美纳降价影响逐步消除 研发加速推进",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "国常会关注医药领域知识产权 六股绝佳布局良机",
            "features": {
                "keywords": [
                    "国常会",
                    "医药",
                    "知识产权",
                    "布局"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "国常会关注医药领域知识产权 六股绝佳布局良机",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]